MedTrace Logo

Efficacy and Safety of Two Simeticone Brands in Adults With Functional Dyspepsia

NCT02660372 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2016-12-15

No results posted yet for this study

Summary

The aim of this study is to show non-inferiority of two brands of simeticone in adult patients suffering from functional dyspepsia.

Conditions

  • Functional Dyspepsia

Interventions

DRUG

Imonogas

Simethicone 120 mg in gel capsules

DRUG

Espumisan

Simethicone 40 mg in gel capsules

Sponsors & Collaborators

  • Johnson & Johnson Consumer and Personal Products Worldwide

    lead INDUSTRY

Principal Investigators

  • Elisabeth Kruse · McNeil AB

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-10-31
Completion
2016-12-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02660372 on ClinicalTrials.gov